Tissue Regenix Group plc
CellRight Technologies signs multi-year distribution agreement with Arthrex, Inc.
Leeds, 06 March 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today announces subsidiary CellRight Technologies ("CellRight") has signed a long-term, multi-year distribution agreement with Arthrex, Inc., a premier innovator of orthopaedic surgical solutions.
CellRight, which produces industry leading verified osteobiologics for use in orthopaedic, spine and foot and ankle procedures, enhances the healing opportunities of defects caused by trauma and disease.
The multi-year commitment will give surgeons access to verified osteobiologics and advanced surgical instrumentation and techniques to help influence better patient outcomes.
"This long-term distribution agreement will allow physicans and patients better access to CellRight's innovative orthobiologics through the Arthrex network," said Jesus Hernandez, CEO for CellRight Technologies. "Our shared vision of offering surgeons total solutions which can positively impact patient outcomes solidifies the decision of both companies to work together."
Steve Couldwell, CEO Tissue Regenix Group plc commented: "This is a flagship distribution agreement for CellRight and the wider Tissue Regenix Group. It highlights the value of strategic partnerships with prestigious companies in this space. We look forward to working with Arthrex to bring the CellRight product portfolio to an extended network of healthcare professionals."
CellRight Technologies and TRX Orthopedics, will be exhibiting at the American Academy of Orthopaedic Surgeons in New Orleans, March 7-10 and can be found at booth #5413.
For more Information:
Tissue Regenix Group plc Caitlin Pearson Head of Communications |
Tel: 0330 430 3073 / 07920272 441 |
Jefferies International Ltd Simon Hardy / Christopher Binks |
Tel: 020 7029 8000 |
FTI Consulting Brett Pollard / Mo Noonan/ Rob Winder |
Tel: 0203 727 1000 |
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', rebranded TRX BioSurgery in February 2018. January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.
